Long-term Safety Study of Alogliptin in Participants With Type 2 Diabetes in Japan
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the long-term safety and efficacy of SYR-322, once
daily (QD), to an α-glucosidase inhibitor, three times daily (TID), administered for 40
consecutive weeks in participants who completed a phase 2 dose-ranging study.